Patents by Inventor Diljeet Singh Athwal

Diljeet Singh Athwal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7977464
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: July 12, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Patent number: 7566771
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 28, 2009
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20080269465
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Application
    Filed: June 18, 2008
    Publication date: October 30, 2008
    Applicant: UCB PHARMA S.A.
    Inventors: DILJEET SINGH ATHWAL, DEREK THOMAS BROWN, ANDREW NEIL CHARLES WEIR, ANDREW GEORGE POPPLEWELL, ANDREW PAUL CHAPMAN, DAVID JOHN KING
  • Patent number: 7262050
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: August 28, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7244832
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: July 17, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7244615
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: July 17, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7241877
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: July 10, 2007
    Assignee: Celltech R&D Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 7186820
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: March 6, 2007
    Assignee: UCB Celltech
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Patent number: 7012135
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: March 14, 2006
    Assignee: Celltech Chiroscience Limited
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Publication number: 20040202662
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Application
    Filed: November 7, 2003
    Publication date: October 14, 2004
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6750325
    Abstract: The invention provides recombinant antibody molecules comprising antigen binding regions derived from the heavy and/or light chain variable regions of a donor anti-CD3 antibody, e.g. OKT3, and which have anti-CD3 binding specificity, preferably of affinity similar to that of OKT3. The recombinant antibody is preferably a humanized antibody and may be a chimeric or CDR-grafted antibody. A method is disclosed for preparing CDR-grafted humanized antibodies in which, in addition to the CDR's non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58, and 71 of the light chain variable region. The recombinant, especially the humanized, anti-CD3 antibodies may be used for in vivo therapy or diagnosis.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: June 15, 2004
    Assignee: Celltech R&D Limited
    Inventors: Linda Kay Jolliffe, Robert Allan Zivin, John Robert Adair, Diljeet Singh Athwal
  • Patent number: 6734286
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: May 11, 2004
    Assignee: Celltech R&D Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20040076627
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-antibodies.
    Type: Application
    Filed: November 7, 2003
    Publication date: April 22, 2004
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20040071693
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24,48) and/or (49,71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positons (46,48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis.
    Type: Application
    Filed: November 7, 2003
    Publication date: April 15, 2004
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20030199679
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF&agr;, are provided for use in diagnosis and therapy. In particular the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF&agr; antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 23, 2003
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
  • Patent number: 6632927
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanized antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 14, 2003
    Assignee: Celltech Therapeutics Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20030039645
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF alpha , are provided for use in diagnosis and therapy. In particular the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF alpha antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Application
    Filed: February 28, 2001
    Publication date: February 27, 2003
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage
  • Publication number: 20030026805
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.
    Type: Application
    Filed: October 18, 2001
    Publication date: February 6, 2003
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Publication number: 20020151682
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.
    Type: Application
    Filed: September 10, 2001
    Publication date: October 17, 2002
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Patent number: RE39548
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: April 3, 2007
    Assignee: Celltech R&D Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage